<DOC>
	<DOCNO>NCT00803907</DOCNO>
	<brief_summary>This study aim prove efficacy safety use imiquimod 5 % cream periorbital region .</brief_summary>
	<brief_title>Imiquimod 5 % Cream Treatment Periocular Basal Cell Carcinoma</brief_title>
	<detailed_description>This prospective study include patient present aggregate primary lesion affect nodular BCC eyelid ( subject submit incisional biopsy 2 mm punch ) commencement study . All submit local treatment Imiquimod 5 % cream ( Aldara Â® ) , daily , 5 day per week 8-16 week ( average ) . All subject submit new incisional biopsy 2 mm punch , 12 week treatment , monitor monthly now.If positive biopsy ( residue tumor ) case manage surgery .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Adjuvants , Immunologic</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Patients whose injury confirm anatomical pathological study ( periocular superficial basal cell carcinoma ) . Patients clinical counter indication reconstructive surgery ( high surgical risk ) . Patients refuse restorative surgery . ( aesthetic reason ) Patients sign free informed consent . Patients hypersensitivity reaction formula component . Children 12 year age . Pregnant breastfeed woman . Patients whose injury confirm anatomical pathological study . Individuals previous autoimmune inflammatory disease . Patients refuse sign free inform term consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>immunomodulator</keyword>
	<keyword>Carcinoma , Basal Cell</keyword>
</DOC>